Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Martin Babler, the company's President and CEO, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 3:20 pm ET. Interested parties can access a live webcast of the presentation through the 'Events' page in the 'Investors' section of the Alumis website.
Alumis (Nasdaq: ALMS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie orali per malattie mediate dal sistema immunitario, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Vita di Oppenheimer. Martin Babler, Presidente e CEO dell'azienda, offrirà una presentazione all'evento virtuale il martedì 11 febbraio 2025, alle 15:20 ET. Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la pagina 'Eventi' nella sezione 'Investitori' del sito web di Alumis.
Alumis (Nasdaq: ALMS), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias orales para enfermedades mediadas por el sistema inmunológico, ha anunciado su participación en la 35ª Conferencia Anual sobre Ciencias de la Salud de Oppenheimer. Martin Babler, presidente y CEO de la empresa, realizará una presentación en el evento virtual el martes 11 de febrero de 2025, a las 3:20 pm ET. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la página 'Eventos' en la sección 'Inversores' del sitio web de Alumis.
Alumis (Nasdaq: ALMS)는 면역 매개 질환을 위한 경구 요법 개발에 중점을 둔 임상 단계의 생명공학 회사로서 오펜하이머 제35회 연례 건강 과학 회의에 참여할 것이라고 발표했다. Martin Babler CEO가 2025년 2월 11일 화요일 오후 3시 20분 ET에 가상 이벤트에서 발표를 진행할 예정이다. 관심 있는 분들은 Alumis 웹사이트의 '투자자' 섹션의 '이벤트' 페이지를 통해 발표의 라이브 웹캐스트에 접속할 수 있다.
Alumis (Nasdaq: ALMS), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies orales pour les maladies à médiation immunitaire, a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Vie d'Oppenheimer. Martin Babler, Président et CEO de l'entreprise, fera une présentation lors de cet événement virtuel le Mardi 11 Février 2025 à 15h20 ET. Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la page 'Événements' dans la section 'Investisseurs' du site web de Alumis.
Alumis (Nasdaq: ALMS), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung oraler Therapien für immunvermittelte Krankheiten konzentriert, hat seine Teilnahme an der 35. Jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Oppenheimer angekündigt. Martin Babler, Präsident und CEO des Unternehmens, wird am Dienstag, den 11. Februar 2025, um 15:20 Uhr ET eine Präsentation bei der virtuellen Veranstaltung halten. Interessierte können über die Seite 'Veranstaltungen' im Abschnitt 'Investoren' der Alumis-Website auf einen Live-Stream der Präsentation zugreifen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.
A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page.
About Alumis
Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies. Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 (TYK2) that is currently being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, Alumis’ proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify its precision approach. Incubated by Foresite Labs and led by a team of industry veterans experienced in small-molecule compound drug development for immune-mediated diseases, Alumis is pioneering a precision approach to drug development to potentially produce the next generation of treatment to address immune dysfunction. For more information, visit www.alumis.com.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
FAQ
When is Alumis (ALMS) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Alumis's (ALMS) Oppenheimer Conference presentation?
What type of therapies is Alumis (ALMS) developing?
Is the Oppenheimer Healthcare Conference 2025 featuring Alumis (ALMS) virtual or in-person?
